Skip to main content

Advertisement

Fig. 5 | Stem Cell Research & Therapy

Fig. 5

From: Chrysosplenetin promotes osteoblastogenesis of bone marrow stromal cells via Wnt/β-catenin pathway and enhances osteogenesis in estrogen deficiency-induced bone loss

Fig. 5

Chrysosplenetin promotes osteogenic gene expression in hBMSCs. RT-pPCR was utilized to evaluate the expression of osteogenic genes. hBMSCs cells were planted and added with OIM and Chrysosplenetin (10 μM) in the presence or absence of Noggin (10 μg/ml) or DKK1 (0.5 μg/ml) for 3, 7, and 14 days. Gene expression was normalized to GAPDH; a RUNX2; b Distal-less Homeobox 5 (DLX5); c Osteopontin (SPP1); d Collagen type I (COL1); e BGLAP; f BMP2 (*p < 0.05, **p < 0.01, ***p < 0.001 relative to Chrysosplenetin treating group)

Back to article page